BioLineRx Ltd. (Nasdaq: BLRX) announced today that Philip A. Serlin has been named Chief Executive Officer of BioLineRx, effective October ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Management Changes Management Comments

Roth Capital Keeps VBL Therapeutics (VBLT) at 'Buy' Following Q2 Results; Glioblastoma Remains in FocusAugust 15, 2016 12:20 PM Roth Remains Positive on BioLineRx (BLRX) Following Q2 Report, CEO SuccessionAugust 11, 2016 11:46 AM BioLineRx (BLRX) Misses Q2 EPS by 2c; Updates on Remaining FY16 MilestonesAugust 11, 2016 7:19 AM BioLineRx Names Philip A. Serlin as Chief Executive OfficerAugust 11, 2016 6:45 AM